1 | themegrill powered by wordpress | | | | | | | 1 | 0.29% |
2 | developing metaanalysis resources for | | | | | | | 1 | 0.29% |
3 | cancer to spread to | | | | | | | 1 | 0.29% |
4 | to spread to other | | | | | | | 1 | 0.29% |
5 | spread to other sites | | | | | | | 1 | 0.29% |
6 | to other sites in | | | | | | | 1 | 0.29% |
7 | other sites in the | | | | | | | 1 | 0.29% |
8 | sites in the body | | | | | | | 1 | 0.29% |
9 | in the body we | | | | | | | 1 | 0.29% |
10 | the body we are | | | | | | | 1 | 0.29% |
11 | developing and using new | | | | | | | 1 | 0.29% |
12 | are developing and using | | | | | | | 1 | 0.29% |
13 | we are developing and | | | | | | | 1 | 0.29% |
14 | metaanalysis resources for head | | | | | | | 1 | 0.29% |
15 | – allowing cancer to | | | | | | | 1 | 0.29% |
16 | resources for head and | | | | | | | 1 | 0.29% |
17 | for head and neck | | | | | | | 1 | 0.29% |
18 | head and neck cancer | | | | | | | 1 | 0.29% |
19 | and neck cancer and | | | | | | | 1 | 0.29% |
20 | diseases we are developing | | | | | | | 1 | 0.29% |
21 | many pathways and biological | | | | | | | 1 | 0.29% |
22 | pathways and biological functions | | | | | | | 1 | 0.29% |
23 | melanoma and developing new | | | | | | | 1 | 0.29% |
24 | and developing new tools | | | | | | | 1 | 0.29% |
25 | developing new tools to | | | | | | | 1 | 0.29% |
26 | new tools to identify | | | | | | | 1 | 0.29% |
27 | allowing cancer to spread | | | | | | | 1 | 0.29% |
28 | body – allowing cancer | | | | | | | 1 | 0.29% |
29 | to identify key subpopulations | | | | | | | 1 | 0.29% |
30 | tissue behaviour we collaborate | | | | | | | 1 | 0.29% |
31 | understand the similarities and | | | | | | | 1 | 0.29% |
32 | cells become brainwashed in | | | | | | | 1 | 0.29% |
33 | become brainwashed in lymph | | | | | | | 1 | 0.29% |
34 | brainwashed in lymph nodes | | | | | | | 1 | 0.29% |
35 | in lymph nodes to | | | | | | | 1 | 0.29% |
36 | lymph nodes to tolerate | | | | | | | 1 | 0.29% |
37 | nodes to tolerate cancer | | | | | | | 1 | 0.29% |
38 | to tolerate cancer cells | | | | | | | 1 | 0.29% |
39 | tolerate cancer cells that | | | | | | | 1 | 0.29% |
40 | we collaborate closely with | | | | | | | 1 | 0.29% |